Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner

Antiviral Therapy

Volumn 17, Issue 4, 2012, Pages 669-678

  Mencarelli, Andrea ^a   Francisci, Daniela ^a   Renga, Barbara ^a   D'Amore, Claudio ^a   Cipriani, Sabrina ^a   Basile, Flavia ^a   Schiaroli, Elisabetta ^a   Baldelli, Franco ^a   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; CD68 ANTIGEN; FATTY ACID; FATTY ACID BINDING PROTEIN 4; FATTY ACID SYNTHASE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; LEFLUNOMIDE; LEPTIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RITONAVIR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CLUSTER OF DIFFERENTIATION 36 GENE; CONTROLLED STUDY; DYSLIPIDEMIA; EPIDIDYMIS FAT; FATTY ACID BINDING PROTEIN 4 GENE; FATTY ACID BLOOD LEVEL; FATTY ACID ELONGASE GENE; FATTY ACID SYNTHASE GENE; FATTY LIVER; GENE EXPRESSION; HISTOPATHOLOGY; HMGCOA REDUCTASE GENE; HMGCOA SYNTHASE GENE; LEPTIN GENE; LEUKOCYTE; LIPID LIVER LEVEL; LIPOATROPHY; LIPOPROTEIN LIPASE GENE; LIVER HISTOLOGY; MOUSE; NONHUMAN; PERLIPIN A GENE; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; PRIORITY JOURNAL; SLC27A1 GENE; STEAROYL COA DESATURASE 1 GENE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C GENE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2 GENE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DYSLIPIDEMIAS; EPIDIDYMIS; FATTY LIVER; HIV PROTEASE INHIBITORS; ISOXAZOLES; LIPODYSTROPHY; MALE; MICE; MICE, INBRED C57BL; PPAR GAMMA; RITONAVIR;

EID: 84861653489     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2039     Document Type: Article

References (48)

1. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116:1793-1801. (Pubitemid 44033299)
2. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000; 30:S135-S142. (Pubitemid 32268981)
3. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-1883. (Pubitemid 28279721)
4. DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
5. Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr 2000; 25:S4-S11.
6. Distler O, Cooper DA, Deckelbaum RJ, Sturley SL. Hyperlipidemia and inhibitors of HIV protease. Curr Opin Clin Nutr Metab Care 2001; 4:99-103. (Pubitemid 34755450)
7. Hadigan C, Meigs JB, Wilson PW, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003; 36:909-916. (Pubitemid 36403525)
8. Ortiz M, Poloni ES, Furrer H, et al. No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy. Swiss HIV Cohort Study. J Infect Dis 2011; 203:620-624.
9. Kolta S, Flandre P, Van PN, et al. Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ ritonavir. Results of the MONARK trial. Curr HIV Res 2011; 9:31-39.
10. Goetzman ES, Tian L, Nagy TR, et al. HIV protease inhibitor ritonavir induces lipoatrophy in male mice. AIDS Res Hum Retroviruses 2003; 19:1141-1150. (Pubitemid 38037384)
11. Dubé MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19:1807-1818. (Pubitemid 41546599)
12. Flint OP, Noor MA, Hruz PW, et al. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol 2009; 37:65-77.
13. Lagathu C, Eustace B, Prot M, et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 2007; 12:489-500. (Pubitemid 47041147)
14. Kim MJ, Leclercq P, Lanoy E, et al. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study. Antivir Ther 2007; 12:1273-1283.
15. Maher B, Lloyd J, Wilkins EG, et al. Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters. Antivir Ther 2004; 9:879-887. (Pubitemid 40040261)
16. Read SW, DeGrezia M, Ciccone EJ, et al. The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants. PLoS ONE 2010; 5:e11937.
17. Périard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100:700-705. (Pubitemid 29383638)
18. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory elementbinding proteins in the nucleus. J Biol Chem 2001; 276:37514-37519.
19. Mencarelli A, Cipriani S, Renga B, et al. The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. PLoS ONE 2010; 5:e13238.
20. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401:73-76.
21. Sekiya M, Yahagi N, Matsuzaka T, et al. SREBP-1-independent regulation of lipogenic gene expression in adipocytes. J Lipid Res 2007; 48:1581-1591. (Pubitemid 47312019)
22. Pulford KA, Sipos A, Cordell JL, Stross WP, Mason DY. Distribution of the CD68 macrophage/myeloid associated antigen. Int Immunol 1990; 2:973-980. (Pubitemid 20330547)
23. Dalen KT, Schoonjans K, Ulven SM, et al. Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferatoractivated receptor-gamma. Diabetes 2004; 53:1243-1252. (Pubitemid 38569010)
24. Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 2004; 27:1660-1667. (Pubitemid 38857441)
25. Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther 2006; 13:248-260. (Pubitemid 44026193)
26. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92:3490-3497. (Pubitemid 47435325)
27. Bouloumié A, Curat CA, Sengenes C, Lolmede K, Miranville A, Busse R. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 2005; 8:347-354. (Pubitemid 40863045)
28. Cancello R, Tordjman J, Poitou C, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006; 55:1554-1561. (Pubitemid 44324107)
29. Kolak M, Westerbacka J, Velagapudi VR, et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007; 56:1960-1968. (Pubitemid 47195815)
30. Sevastianova K, Sutinen J, Kannisto K, Hamsten A, Ristola M, Yki-Järvinen H. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 2008; 295:E85-E91.
31. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031. (Pubitemid 34286541)
32. Brasaemle DL. Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. J Lipid Res 2007; 48:2547-2559. (Pubitemid 350272839)
33. Pistell PJ, Gupta S, Knight AG, et al. Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice. Antiviral Res 2010; 88:334-342.
34. Riddle TM, Fichtenbaum CJ, Hui DY. Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice. J Acquir Immune Defic Syndr 2003; 33:564-570. (Pubitemid 36975843)
35. Goetzman ES, Tian L, Nagy TR, et al. HIV protease inhibitor ritonavir induces lipoatrophy in male mice. AIDS Res Hum Retroviruses 2003; 19:1141-1150. (Pubitemid 38037384)
36. Prot M, Heripret L, Cardot-Leccia N, et al. Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice. Antimicrob Agents Chemother 2006; 50:3998-4004. (Pubitemid 44865141)
37. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11:98-107.
38. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000; 165:5962-5969.
39. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK. Transcriptional activation by peroxisome proliferatoractivated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 1997; 272:5128-5132. (Pubitemid 27090069)
40. Zhou H, Jarujaron S, Gurley EC, et al. HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR. Atherosclerosis 2007; 195:e134-e143. (Pubitemid 47561971)
41. Suganami T, Tanimoto-Koyama K, Nishida J et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007; 27:84-91. (Pubitemid 46370478)
42. Cawthorn WP, Sethi JK. TNF-alpha and adipocyte biology. FEBS Lett 2008; 582:117-131.
43. Ekins S, Kholodovych V, Ai N, et al. Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol 2008; 74:662-672.
44. O'Donnell EF, Saili KS, Koch DC, et al. The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor. PLoS ONE 2010; 5:e13128.
45. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30:795-804. (Pubitemid 34671092)
46. Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008; 134:556-567.
47. Lee JH, Wada T, Febbraio M, et al. A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology 2010; 139:653-663.
48. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-1888. (Pubitemid 37070273)